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Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene are the most common cause of familial Parkinson’s
disease (PD) [20, 32]. Common polymorphisms in
LRRK2 have been shown to modulate the risk for spor-
adic PD [6, 23, 24] strengthening the idea that inherited
and sporadic PD share common underlying pathways.
Although LRRK2 has been associated with a variety of
cellular functions, including autophagy [1], mitochon-
drial function/dynamics [30] and microtubule/cytoskel-
etal dynamics [12], the overall physiological function of
LRRK2 and its role in PD are only partially understood.
Relatively recent studies also support a role for LRRK2
as regulator of inflammation. Substantial levels of
LRRK2 protein and mRNA have been reported in
immune cells like peripheral blood mononuclear cells
(PBMCs), including B-cells, monocytes/macrophages,
and dendritic cells [9, 13, 16, 29]. Moreover, LRRK2 has
been shown to be involved in the activation and matur-
ation of immune cells [29], in controlling the radical
burst against pathogens in macrophages [9] and in
modulating neuroinflammation by cytokine signaling
[10, 19]. Remarkably, elevated levels of serum cytokines
(IL-2, IL-4, IL-6, IL-10, TNFα) in PD patients [4, 22, 27]
point to an involvement of the peripheral immune
system in the pathogenesis of PD. Recently, we found an
enrichment of “classical” CD14++CD16− monocyte
subpopulation in the peripheral blood of PD patients to-
gether with a dysregulation of inflammatory pathways,
phagocytosis deficits as well as hyperactivation of PD
monocytes in response to LPS treatment, which corre-
lated to PD severity [11]. Here, we sought to study the
contribution of LRRK2 to the dysregulation of mono-
cytes in Parkinson’s disease.
We set out to obtain a comprehensive picture of
LRRK2 levels in circulating monocyte subpopulations as
well as in lymphoid B-cells in PD patients. To determine
the intracellular LRRK2 protein levels in the different
immune cells we established a flow cytometry-based
technique for intracellular LRRK2 staining. To verify the
specificity of the anti-LRRK2 antibody used in this study
[Novus Biologicals (NB300-268AF647)] isolated murine
spleen cells from LRRK2 knockout (KO) mice [14] and
mice overexpressing human wild-type (WT) LRRK2
(LRRK2 WT-OX mice) [17, 28] were processed, stained
and analyzed as described in the supplementary material
and method section (Additional file 1). While we found
a highly LRRK2-positive population with the Novus anti-
body in spleen samples of LRRK2 WT-OX mice (black
histogram Fig. 1a) no unspecific staining was found in
LRRK2 KO mice (dark grey histogram Fig. 1a) or with
the isotype control (IgG ctrl.) in spleen samples of
LRRK2 WT-OX mice (light grey histogram Fig. 1a).
We used a combination of our well established five-co-
lor FACS analysis strategy [5, 11] to distinguish “clas-
sical” CD14++CD16− (hereinafter referred to as CD14++)
monocytes and “non-classical” CD14dimCD16+ (herein-
after referred to as CD16+) monocytes together with the
intracellular LRRK2 staining. We found that both mono-
cyte subpopulations were LRRK2 positive (orange histo-
grams Fig. 1b), while the IgG and unstained controls did
not show any significant staining (dark and light grey
histograms Fig. 1b). Strikingly, we found significantly
higher LRRK2 protein levels in CD16+ monocytes (upper
panel Fig. 1c) as well as in CD14++ monocytes (lower
panel Fig. 1c) of PD patients (n = 26; mean age
71.0 years) compared to age- and sex matched healthy
controls (n = 26; mean age 68.7 years). Of note,
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probands with confounding factors affecting the im-
mune system were excluded from all experiments (a
detailed description of the proband cohort can be
found in Additional file 1: Table S1). Similar results
of elevated LRRK2 levels in monocytes from PD
patients were also confirmed with two additional
monoclonal anti-LRRK2 antibodies from abcam
(MJFF5 (68–7) and UDD3 30(12)) (Additional file 2).
Since monocytes only represent ~ 6–12% of PBMCs
[2] we also asked whether endogenous LRRK2 levels are
altered in the remaining cell population predominantly
comprising lymphocytes. T cells are devoid of LRRK2
[29], we thus focused on studying LRRK2 levels in
B-cells of PD patients and healthy controls. Of note, we
observed a significant reduction in the number of B-cells
which has also been described earlier [21, 26] (data not
shown). However, as demonstrated in Fig. 1d we did not
detect altered LRRK2 protein levels in CD19+ B-cells be-
tween PD patients (n = 13; mean age 68.1 years) and
controls (n = 17; mean age 71.4 years), indicating that
LRRK2 levels are specifically increased in monocytes of
PD patients. Our findings may explain previous results
Fig. 1 LRRK2 protein expression is significantly upregulated in
monocytes from PD patients. a Spleen cells from LRRK2 KO and
LRRK2 WT-OX mice were used to validate the suitable application of
the rabbit-anti-LRRK2 antibody conjugated to AlexaFluor®647 from
Novus Biologicals (NB300-268AF647) for intracellular flow cytometry
analyses. The antibody showed a highly positive LRRK2 population
in LRRK2 WT-OX cells (black histogram), whereas no LRRK2 staining
was presented within KO cells (dark grey histogram), nor in LRRK2
WT-OX cells stained with the monoclonal rabbit isotype control (light
grey histogram). The displayed experiment shows the fluorescence
intensity of the different samples and is representative of three
independent experiments. b Further validation experiments of
intracellular LRRK2 staining for FACS analyses were performed
with human whole blood samples. The human CD14++ and
CD16+ monocyte subpopulations showed positive staining for
LRRK2 [anti-LRRK2 (Novus); orange histogram], while the isotype
control staining did not show any nonspecific binding (‘IgG control’;
dark grey histogram). The displayed graphs are representative of three
independent experiments. c Leukocytes from whole blood samples of
healthy controls (HC; n= 26) and PD patients (PD; n= 26) were analyzed
by flow cytometry to detect LRRK2 protein in the different monocyte
subsets. CD16+ monocytes (upper panel) as well as CD14++ monocytes
(lower panel) from PD patients displayed significantly higher LRRK2
expression compared to respective monocyte subsets from
healthy controls. The histograms on the right are representative
for the analyzed individuals and display the fluorescence intensity of
the anti-LRRK2-AlexaFluor®647 antibody. The higher LRRK2 expression
in monocytes of PD patients compared to healthy controls is
demonstratively shown in these graphs. d Flow cytometric analyzes of
CD19+ B-cells reveal no changes in the LRRK2 protein expression
between healthy controls (n = 13) and PD patients (n = 17). The
histograms on the right hand side represent the fluorescence intensity
of the anti-LRRK2-AlexaFluor®647 antibody and show overlapping
peaks which reveal no differences in LRRK2 expression. Error bars
represent mean ± SEM; **p < 0.01; statistical significance was
tested with non-parametric testing
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showing no increase in LRRK2 protein levels in PD
patients’ PBMCs [7] since the increase of LRRK2 protein
in monocytes may be masked by unchanged LRRK2
levels in B-cells.
Previously, we have shown a dysregulation of monocyte
subpopulations in the peripheral blood of PD patients
[11]. Having now found that LRRK2 levels are elevated in
PD monocytes, we next asked whether this LRRK2
increase might be involved in monocyte subtype dysregula-
tion. Consequently, we assessed monocyte subpopulations
in a LRRK2(R1441G) BAC transgenic mouse model overex-
pressing the mutant form of human LRRK2, recapitulating
main features of Parkinson’s disease [17]. In mice CD14++
monocytes correspond to Ly6Chigh monocytes and CD16+
monocytes to Ly6Clow monocytes [15]. Using six-color flow
cytometry [3, 8] LRRK2(R1441G) mice showed a marked age-
dependent increase in the ratio of Ly6Chigh to Ly6Clow
monocytes (Fig. 2a) compared to non-transgenic littermates
which was most prominent at 20 month of age. Also in
LRRK2 WT-OX mice we found a trend for an increase in
the ratio of Ly6Chigh to Ly6Clow monocytes, although statis-
tical significance was not reached (Fig. 2b). To additionally
control that LRRK2 overexpression was persistent in
PBMCs from LRRK2 WT-OX mice we performed RT-PCR
and found a robust human LRRK2 expression in PBMCs
from LRRK2 WT-OX mice but not in non-transgenic (NT)
littermates (Fig. 2c), further strengthening the contribution
of LRRK2 in shifting monocyte subpopulations in LRRK2
overexpressing mice.
In summary, we found elevated LRRK2 levels in CD14
++ and CD16+ monocyte subsets of PD patients, but not
in patients’ B-cells. Furthermore, similar to the dysregu-
lation of monocyte subpopulations found in PD patients
[11], a dysregulation of monocyte subpopulations was
detected in LRRK2 overexpressing mice. Our results add
to the growing body of evidence that LRRK2 plays an
important role not only in neuronal cells but also in
immune cells. LRRK2 has been implicated in aspects of
monocyte function including monocyte maturation [29],
adhesion, migration, and inflammation [18, 19]. Further-
more, LRRK2 is hierarchically clustered in the tyrosine-
kinase like superfamily nearby kinases that are important
for inflammatory signaling in immune activation [31].
Moreover, LRRK2 is supposed to function as a stress re-
sponse kinase since inhibition of LRRK2 in innate
immune cells attenuates pro-inflammatory signaling in
response to TLR4 activation [19]. During bacterial phago-
cytosis, LRRK2 translocates near bacterial membranes,
and knockdown of LRRK2 interrupts ROS production
during phagocytosis and diminishes destruction of intra-
cellular bacteria [9]. LRRK2 is not only found in different
immune cells but becomes further upregulated upon
exposure to different pathological stimuli like interferon γ
(IFNγ) [9], microbial structures [lipopolysaccharide (LPS)]
[10, 13] or viral particles [13]. Our current observation
that LRRK2 levels are elevated in monocytes of PD
patients establishes a compelling link between a specific
role of LRRK2 in immune cells and their contribution to
Fig. 2 Differences in the monocyte subset ratio of human LRRK2
overexpressing mice. a, b Ly6Chigh and Ly6Clow monocyte subsets of
mouse models for PD were analyzed by six-color flow cytometry. a
A significant increase in the ratio of Ly6Chigh to Ly6Clow monocyte
subsets was detected in 20 month old mutant LRRK2(R1441G) BAC
transgenic mice in comparison to NT littermates. b A trend of
an increasing ratio of Ly6Chigh to Ly6Clow monocytes of LRRK2
WT-OX mice compared to NT littermates were identified in
20 month old animals. Error bars represent mean ± SEM, *p < 0.05; ns:
not significant; statistical significance was tested with 2way ANOVA (c)
Murine PBMCs were isolated from whole blood samples and isolated
RNA was transcribed into cDNA. PCR products were visualized on a 2%
agarose-gel. A band with 153 bp represent human LRRK2 and is only
detected in PBMCs from LRRK2 WT-OX mice and not in NT littermates;
−RT: negative reverse transcription control, NT: non-transgenic
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PD pathogenesis. Together with the recent study by
Speidel et al. demonstrating a reduction in the non-classical
CD14+CD16+ monocyte subpopulation in PD LRRK2
mutant cells [25] our study forms strong evidence for the
involvement of LRRK2 in PD monocyte dysregulation. Our
current study also supports the idea that PD monocytes are
in a pro-inflammatory predisposition as described earlier
[11] and it might be that together with the co-occurrence
of “second hits” like environmental cues or CNS factors
triggering the peripheral immune system LRRK2 might be
upregulated in monocytes. Together with our findings on a
LRRK2-dependent dysregulation of monocytes in a PD
mouse model, these results strengthen the idea of a central
role of LRRK2 in immune cells and its contribution in
peripheral inflammation in PD. Clearly, more studies are
needed to determine the role of elevated LRRK2 levels in
PD monocytes, its role in dysregulation of monocyte
subpopulations and in modulating inflammatory cytokine
production. Moreover, the signaling pathways and the
pathogenic stimulus actually leading to LRRK2 upregula-
tion need to be determined. Our findings establish a basis
for future studies on LRRK2-dependent monocyte
dysregulation, peripheral inflammation and its contri-
bution to PD pathogenesis.
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